Botanipharm

Botanipharm is a botanical biotechnology company specializing in the development of standardized medicinal plant extracts, with a core focus on Goldenseal (Hydrastis canadensis). Founded as a spin-off from the University of Georgia, the company addresses the critical need for chemical consistency and sustainable sourcing in the botanical industry. Botanipharm utilizes proprietary forest-farming techniques to produce high-potency extracts that are evaluated for their antimicrobial and anti-inflammatory properties. The company's lead program has been investigated in Phase 2 clinical trials for the treatment of urinary tract infections, aiming to provide a scientifically validated botanical alternative to conventional antibiotics. Botanipharm's approach combines traditional ethnobotanical knowledge with modern pharmacological rigor to develop therapies for infectious and inflammatory diseases. By applying pharmaceutical-grade standards to botanical production, the company seeks to provide reliable, evidence-based alternatives to traditional herbal supplements.